What is the ticker symbol for Janux Therapeutics?

Janux Therapeutics trades under the ticker JANX on NASDAQ.

What sector does Janux Therapeutics operate in?

Janux Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze JANX in a portfolio?

PortView shows JANX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Janux Therapeutics (JANX) Stock Analysis

NASDAQHealthcareBiotechnology

$19.64+3.97%

1-year price historyRange $12.18 – $34.74

52-week range$19.64

$12.12$35.34

What Janux Therapeutics does

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Key metrics

Market cap

$1.20B

P/E (TTM)

-11.98

EPS (TTM)

$-1.64

Beta

2.51

Dividend yield

0.00%

Revenue / share

$0.51

50-day avg

$16.26

200-day avg

$15.71

52-week high

$35.34

52-week low

$12.12

CEO

David Alan Campbell

ETFs linked to JANX

Broad-market and Healthcare sector ETFs an investor holding Janux Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how JANX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze JANX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Janux Therapeutics?: Janux Therapeutics trades under the ticker JANX on NASDAQ.
Which exchange is JANX listed on?: JANX is listed on NASDAQ.
What sector does Janux Therapeutics operate in?: Janux Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze JANX in a portfolio?: PortView shows JANX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.